

November 25, 2009

CURRICULUM VITAE
Bernard F. Cole

ADDRESS:

College of Engineering and Mathematical Sciences
109 Votey Hall
33 Colchester Ave.
University of Vermont
Burlington, VT 05405
Telephone: 802-656-8413
Fax: 802-656-8802
E-mail: ccole@cems.uvm.edu

EDUCATION:

1985	B.A.	Mathematics (cum laude)	Boston University
1986	M.A.	Mathematics	Boston University
1992	Ph.D.	Mathematics	Boston University

POSTDOCTORAL TRAINING:

1992–1993 Postdoctoral Research Fellow, Department of Biostatistics, Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, MA.

ACADEMIC APPOINTMENTS:

1993–1997 Assistant Professor of Community Health (Research), Department of Community Health and Center for Statistical Sciences, Brown University, Providence, RI.

1997–2001 Assistant Professor of Community and Family Medicine (Biostatistics), Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, NH.

2001–2007 Associate Professor of Community and Family Medicine (Biostatistics), Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, NH.

2003–2005 Visiting Assistant Professor of Mathematics, Dartmouth College, Hanover, NH.

2005–2007 Adjunct Associate Professor of Mathematics, Dartmouth College, Hanover, NH.

2007– Professor of Community and Family Medicine (Biostatistics), Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, NH.

2007– Professor of Statistics and Statistics Program Director, Department of Mathematics and Statistics, College of Engineering and Mathematical Sciences, University of Vermont, Burlington, VT.

2009– Interim Dean, College of Engineering and Mathematical Sciences, University of Vermont, Burlington, VT.

HOSPITAL APPOINTMENTS:

- 1984–1985 Statistical Programmer/Consultant, Joslin Diabetes Center, Boston, MA.
- 1990–1993 Statistician, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA.
- 1993–1997 Statistician, Roger Williams Medical Center, Providence, RI.
- 1993–1997 Group Statistician, Brown University Oncology Group, Providence, RI.
- 2002–2007 Director, Biostatistics Shared Resource, Norris Cotton Cancer Center, Lebanon, NH.

OTHER APPOINTMENTS:

- 1983 Programmer, Institute for High-Frequency Physics, Wachtberg-Berkum, Germany.
- 1984 Statistical Programmer, McBer and Company, Boston, MA.
- 1984 Statistical Programmer, Center for Technology and Policy, Boston University, Boston, MA.
- 1985–1990 Statistical Programmer/Consultant, Office of Information Technology, Boston University, Boston, MA.
- 1991–1992 Statistician, Dana-Farber Cancer Institute, Boston, MA.

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

- 1992– American Statistical Association
- 1992– Biometric Society, Eastern North American Region
- 1996– American Society of Clinical Oncology

INVITED PRESENTATIONS:

1. July 1991, Boston University – “Cost-benefit analysis with competing risks models.”
2. February 1993, Harvard University – “Regression models for quality adjusted survival analysis.”
3. July 1993, Pfizer, Inc. – “Regression models for quality adjusted survival analysis.”
4. July 1993, Brown University – “Regression models for quality adjusted survival analysis.”
5. November 1993, University of Connecticut – “Empirical Bayes procedures for Markov dependent binary sequences with missing observations.”
6. November 1993, Brown University – “Empirical Bayes procedures for Markov dependent binary sequences with missing observations.”
7. December 1993, Schering-Plough, Inc. – “Comparing treatments using quality adjusted survival: the Q-TWiST method.”
8. March 1994, McGill University – “Empirical Bayes procedures for Markov dependent binary sequences with missing observations.”
9. June 1994, International Research Conference on Lifetime Data Models in Reliability and Survival Analysis, Harvard University – “Regression methods for quality adjusted survival analysis in clinical trials.”
10. August 1994, Joint Statistical Meetings, Toronto – “Cost-effectiveness analysis using quality-of-life-adjusted survival.”
11. January 1995, ASA Winter Conference, Raleigh, NC – “Cost-effectiveness analysis using quality-of-life-adjusted survival.”

12. May 1995, McMaster University – “Comparing treatments using quality adjusted survival: the Q-TWiST method.”
13. October 1995, Alpha Interferon Therapy: A Clinical and Pharmacoeconomic Perspective, Madrid, Spain – “A quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma.”
14. November 1995, National Melanoma Speakers Meeting, Boca Raton, Florida – “Interferon Alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: a quality-of-life-adjusted survival analysis.”
15. May 1996, Dana-Farber Cancer Institute, Boston, Massachusetts – “Recent statistical advancements in quality-adjusted survival analysis.”
16. June 1996, VI International Conference on Malignant Lymphoma Satellite Symposium: Immunotherapy of Non-Hodgkin's Lymphoma, Lugano, Switzerland – “Quality of life in low grade lymphoma, a Q-TWiST analysis of the GELF trial.”
17. September 1996, Perspectives in Melanoma 1996 Symposium, Pittsburgh, Pennsylvania – “A quality-of-life-adjusted analysis of adjuvant high dose interferon alfa-2b therapy.”
18. November 1996, RIBI ImmunoChem, Inc. – “Quality-of-life-adjusted survival analysis in clinical trials.”
19. January 1997, University of Pittsburgh – “Recent statistical advancements in quality-of-life-adjusted survival analysis.”
20. February 1997, Dartmouth Medical School – “Recent statistical advancements in quality-of-life-adjusted survival analysis.”
21. February 1997, Cornell University – “Quality-of-life-adjusted survival analysis in clinical trials.”
22. March 1997, Winter Oncology Conference, Banff, Canada – “Evaluation of trade-offs in the treatment of cancer: the Q-TWiST method.”
23. March 1997, Trends in Melanoma Management, Charleston, South Carolina – Evaluating trade-offs in clinical trials: the Q-TWiST method.”
24. March 1997, The Latest Word on Interferon Therapy, Miami, Florida – “Quality-adjusted survival analysis of interferon therapy for melanoma and non-Hodgkin's lymphoma.”
25. April 1997, John Wayne Cancer Institute, Santa Monica, California – “Evaluating trade-offs in clinical trials: the Q-TWiST method.”
26. November 1998, Northwestern University, Chicago, Illinois – “Utilities and quality of life of prostate cancer treatments.”
27. March 1999, Biometric Society, Eastern North American Region 1999 Spring Meeting, Atlanta, Georgia – “Quality-of-life adjusted survival in clinical trials—design and analysis considerations.”
28. May 1999, A Symposium on Longitudinal Studies of Quality of Life, Johns Hopkins University, Baltimore, Maryland – “Quality-of-life adjusted analysis.”
29. June 2000, Schering-Plough Workshop: Measurement and Analysis of Quality-of-Life Outcomes for Drug Development, Harvard School of Public Health, Boston, Massachusetts – “Quality-of-life-adjusted survival in clinical trials.”
30. September 2000, Early Breast Cancer Trialists' Collaborative Group Fifth Main Meeting, Oxford University, Oxford, UK – “Overview analysis using Q-TWiST.”
31. October 2000, International Workshop on Statistical Design, Measurements and Analysis of Health Related Quality of Life, University of South Brittany “Quality-of-life-adjusted survival analysis in clinical trials.”

32. July 2001, Schering-Plough, Inc., Kenilworth, New Jersey – “Q-TWiST for advanced stage cancer.”
33. June 2004, International Society of Quality of Life Meetings, Boston, Massachusetts – “Q-TWiST Workshop.”
34. May 2005, American College of Radiology, Philadelphia, PA – “Quality-of-Life-Adjusted Survival Analysis: The Q-TWiST method.”
35. February 2006, Massachusetts General Hospital Institute for Technology Assessment – “Quality-of-Life-Adjusted Survival Analysis: The Q-TWiST method.”
36. April 2006, University of Chicago, Chicago, IL – “Statistical Challenges in Quality-of-Life Research.”
37. April 2006, University of Vermont, Burlington, VT – “Statistical Challenges in Quality-of-Life Research.”
38. March 2008, University of Vermont, Burlington, VT, Program for Research in Medical Outcomes – “Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-Analysis of the Randomized Trials”
39. May 2008, University of Vermont, Burlington, VT, Vermont Cancer Center Grand Rounds – “A Randomized Trial of Folic Acid for the Prevention of Colorectal Adenomas”
40. April 2009, United States Food and Drug Administration, Silver Spring, MD – “Statistical Experiences in Randomized Clinical Trials”

CONTRIBUTED PRESENTATIONS:

1. August 1991, Joint Statistical Meetings, Atlanta, GA – “Cost-benefit analysis with competing risks models.”
2. May 1992, Meeting of the Society for Clinical Trials, Philadelphia, PA – “Parametric approaches to quality adjusted survival analysis.”
3. March 1993, Biometric Society ENAR Meetings, Philadelphia, PA – “Logistic regression for Markov dependent Bernoulli trials with randomly missing observations.”
4. April 1994, Biometric Society ENAR Meetings, Cleveland, OH – “A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer.”
5. August 1994, Joint Statistical Meetings, Toronto – “Empirical Bayes procedures for Markov dependent binary sequences with missing observations.”
6. December 1995, The American Society of Hematology 37th Annual Meeting and Exposition, Seattle, WA – “Interferon alfa for the treatment of advanced follicular lymphoma: an analysis of quality-of-life-adjusted survival.”
7. March 1996, American Academy of Neurology 48th Annual Meeting, San Francisco, CA – “The meaning of a negative cerebrospinal fluid cytology.”
8. May 1996, American Society of Clinical Oncology Annual Meeting, Philadelphia, PA – “A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study.”
9. May 1996, American Society of Clinical Oncology Annual Meeting, Philadelphia, PA – “Evaluation of quality-of-life adjusted survival in patients with malignant gliomas” (poster).
10. May 1998, American Society of Clinical Oncology Annual Meeting, Los Angeles, CA – “Quality-adjusted time without symptoms and toxicity (Q-TWiST) comparison of Melacine versus combination chemotherapy for patients with stage IV melanoma” (poster).

11. August 2002, Joint Statistical Meetings, New York – “A Multistate Markov Chain Model for Longitudinal Quality-of-Life Data Subject to Non-Ignorable Missingness.”
12. April 2005, American Association of Cancer Research, Anaheim, CA – “A Randomized Trial of Folic Acid to Prevent Colorectal Adenomas.”

UNDERGRADUATE TEACHING ROLES

- 1999 Applied Linear Regression (Math 30) – Dartmouth College
- 2001 Applied Linear Regression (Math 30) – Dartmouth College
- 2002 Introductory Statistics (Math 10) – Dartmouth College
- 2002 Applied Linear Regression (Math 30) – Dartmouth College
- 2003 Applied Linear Regression (Math 30) – Dartmouth College
- 2004 Applied Linear Regression (Math 30) – Dartmouth College
- 2005 Applied Linear Regression (Math 30) – Dartmouth College
- 2008 Basic Statistical Methods (Stat 141) – University of Vermont

GRADUATE TEACHING ROLES

- 1994 Introduction to Probability and Statistics in Biology and Medicine (BI/C213) – Brown University
- 1995 Graduate Seminar in Epidemiology – Brown University
- 1995 Introductory Biostatistics (BI/C015) – Brown University
- 1996 Longitudinal Data Analysis (BI/C291) – Brown University
- 1996 Analysis of Lifetime Data (BI/C291) – Brown University
- 1998 Biostatistics and Epidemiology – Dartmouth Medical School
- 1998 Quantitative Methods (ECS 291) – Dartmouth College
- 1999 Biostatistics and Epidemiology – Dartmouth Medical School
- 1999 CECS Doctoral Seminar – Dartmouth College
- 2000 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2001 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2002 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2003 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2004 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2004 Advanced Statistical Methods (ECS 245) – Dartmouth College
- 2005 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2005 Advanced Statistical Methods (ECS 245) – Dartmouth College
- 2006 Advanced Statistical Methods (ECS 245) – Dartmouth College
- 2006 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2007 Advanced Statistical Methods (ECS 245) – Dartmouth College
- 2007 Biostatistics and Epidemiology (Course Director) – Dartmouth Medical School
- 2007 Directed reading in Biostatistics – Dartmouth Medical School
- 2008 Linear Models (STAT 360) – University of Vermont
- 2008 Statistical Methods I (STAT 211) – University of Vermont
- 2009 Statistical Methods I (STAT 211) – University of Vermont
- 2009 Linear Models (STAT 360) – University of Vermont

JOURNAL EDITORSHIPS:

1. Statistical Editor, *Journal of the National Cancer Institute*

2. Associate Editor, *Lifetime Data Analysis*

DOCTORAL DISSERTATION COMMITTEES

- Patrick Gillen (Brown University Department of Applied Mathematics, 1996)
Matthew Hudson (Dartmouth College Center for Evaluative Clinical Sciences, 2003)
Kristin Wallace (Dartmouth College Center for Evaluative Clinical Sciences, 2005)
Karen Homa (Dartmouth College Center for Evaluative Clinical Sciences, 2006)
Marie-Claire Rosenberg (Dartmouth College Center for Evaluative Clinical Sciences, 2008)

OTHER PROFESSIONAL SERVICE:

1. Site visit reviewer for a Program Project Grant application submitted to the National Cancer Institute (1999)
2. Member of the Data Monitoring Board for the VA Cooperative Study 402: “VA topical tretinoin chemoprevention trial” (1999–2004)
3. Clinical Oncology (CONC) Study Section for the National Institutes of Health (2000–2005)
4. SPORE Application Study Section for the National Institutes of Health (2001–2003)
5. Member of the Behavioral and Health Outcomes committee of the National Surgical Breast and Bowel Project (2003–)
6. Epidemiology of Cancer Study Section for the National Institutes of Health (2006–)
7. Site visitor for a Cancer Center Support Grant application submitted to the National Cancer Institute (2007)

PUBLICATIONS (PEER-REVIEWED):

1. Gelber, R.D., Lenderking, W.R., Cotton, D.J., Cole, B.F., Fischl, M.A., Goldhirsch, A. and Testa, M.A. (1992). Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. *Annals of Internal Medicine* **116**, 961–966.
2. Gelber, R.D., Goldhirsch, A. and Cole, B.F. (1993). Evaluation of effectiveness: Q-TWiST. *Cancer Treatment Reviews* **19** (Supplement A), 73–84.
3. Cole, B.F., Gelber, R.D. and Goldhirsch, A. (1993). Cox regression models for quality adjusted survival analysis. *Statistics in Medicine* **12**, 975–987.
4. Gelber, R.D., Goldhirsch, A. and Cole, B.F. (1993). Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. *Controlled Clinical Trials* **14**, 485–499.
5. Lenderking, W.R., Gelber, R.D., Cotton, D.J., Cole, B.F., Goldhirsch, A., Volberding, P.A. and Testa, M.A. (1994) for the AIDS Clinical Trials Group. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. *New England Journal of Medicine* **330**, 738–743.
6. Cole, B.F., Gelber, R.D. and Anderson, K.M. (1994). Parametric approaches to quality adjusted survival analysis. *Biometrics* **50**, 621–631.
7. Nord, K.D., Dore, D.D., Deeney, V.F., Armstrong, M.A., Cundy, P.J., Cole, B.F. and Ehrlich, M.G. (1995). Evaluation of treatment modalities for septic arthritis with histologic grading and analysis of levels of uronic acid, neutral protease and interleukin-1. *Journal of Bone and Joint Surgery* **77-A**, 258–265.
8. Schwartz, C.E., Cole, B.F., Vickrey, B. and Gelber, R.D. (1995). The Q-TWiST approach to assessing health-related quality of life in epilepsy. *Quality of Life Research* **4**, 135–141.

9. Cole, B.F., Gelber, R.D. and Goldhirsch, A. (1995). A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. *Statistics in Medicine* **14**, 1771–1784.
10. Glantz, M.J., Hall, W.A., Cole, B.F., Chozick, B.S., Shannon, C.M., Wahlberg, L., Akerley, W., Marin, L. and Choy, H. (1995). Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. *Cancer* **75**, 2919–2931.
11. Gelber, R.D., Cole, B.F., Gelber, S. and Goldhirsch, A. (1995). Comparing treatments using quality-adjusted survival: the Q-TWiST method. *American Statistician* **49**, 161–169.
12. Gelber, R.D., Cole, B.F., Goldhirsch, A., Bonadonna, G., Howell, A., McArdle, C.S., Mouridsen, H.T., Rubens, R.D., Welvaart, K. (1995). Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. *The Cancer Journal* **1**, 114–121.
13. Schwartz, C.E., Cole, B.F. and Gelber, R.D. (1995). Measuring patient-centered outcomes in neurologic disease: extending the Q-TWiST methodology. *Archives of Neurology* **52**, 754–762.
14. Cole, B.F., Lee, M.-L.T., Whitmore, G.A. and Zaslavsky, A.M. (1995). An empirical Bayes procedure for Markov dependent binary sequences with randomly missing observations. *Journal of the American Statistical Association* **90**, 1364–1372.
15. Choy, H., Yee, L. and Cole, B. (1995). Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. *Seminars in Oncology*, **22**, 38–44.
16. Glantz, M.J., Choy, H., Kearns, C.M., Cole, B.F., Mills, P., Zuhowski, E.G., Saris, S., Rhodes, C.H., Stopa, E., and Egorin, M.J. (1996). Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. *Journal of Clinical Oncology* **14**, 600–609.
17. Glantz, M.J., Cole, B.F., Friedberg, M.H., Lathi, E., Choy, H., Furie, K., Akerley, W., Wahlberg, L., Lekos, A. and Louis, S. (1996). A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. *Neurology* **46**, 985–991.
18. Gelber, R.D., Cole, B.F., Goldhirsch, A., Rose, C., Fisher, B., Osborne, C.K., Boccardo, F., Gray, R., Gordon, N.H., Bengtsson, N.-O. and Sevelde, P. (1996). Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: a meta-analysis using quality-adjusted survival. *The Lancet* **347**, 1066–1071.
19. Gelber, R.D., Goldhirsch, A., Cole, B.F., Wieand, H.S., Schroeder, G., Krook, J.E. (1996). A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. *Journal of the National Cancer Institute* **88**, 1039–1045.
20. Safran, H., King, T., Choy, H., Gollerkeri, A., Kwakwa, H., Lopez, F., Cole, B., Myers, J., Tarpey, J., Rosmarin, A. (1996). p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung cancer. *Cancer* **78**, 1203–1210.
21. Cole, B.F., Gelber, R.D., Kirkwood, J.M., Goldhirsch, A., Barylak, E. and Borden, E. (1996). A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study (E1684). *Journal of Clinical Oncology* **14**, 2666–2673.
22. Clark, J., Sikov, W., Cummings, F., Browne, M., Akerley, W., Wanebo, H., Weitberg, A., Kennedy, T., Cole, B., Bigley, J., Beitz, J. and Darnowski, J. (1996). Phase II study of 5-

- fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. *Journal of Cancer Research and Clinical Oncology* **122**, 554–558.
23. Glantz, M.J., Choy, H., Akerley, W., Kerns, C.M., Egorin, M.J., Rhodes, C.H. and Cole, B.F. (1996). Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics and response. *Seminars in Oncology* **23** (Supplement 4), 128–135.
 24. White, R.E., Vezeridis, M.P., Konstadoulakis, M., Cole, B.F., Wanebo, H.J., and Bland, K.I. (1996). Therapeutic options and results for the management of minimally invasive breast cancer: influence of axillary dissection for treatment of T1a and T1b lesions. *Journal of the American College of Surgeons* **183**, 575–582
 25. Kirkwood, J.M., Resnick, G.D. and Cole, B.F. (1997). Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. *Seminars in Oncology* **24** (Supplement 4), 16–23.
 26. Mustafa, I.A., Cole, B.F., Wanebo, H.J., Bland, K.I., and Chang, H.R. (1997). The impact of histopathology on nodal metastases in minimal breast cancer. *Archives of Surgery* **132**, 384–391.
 27. Wanebo, H.J., Cole, B., Chung, M., Vezeridis, M., Schepps, B., Fulton, J. and Bland, K. (1997). Is surgical management compromised in elderly patients with breast cancer? *Annals of Surgery* **225**, 579–589.
 28. Pricolo, V.E., Finkelstein, S.D., Hanson, K., Cole, B.F., and Bland, K.I. (1997). Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. *Archives of Surgery* **132**, 371–375.
 29. Chung, M.A., Cole, B., Wanebo, H.J., Bland, K.I. and Chang, H.R. (1997). Optimal surgical treatment of invasive lobular carcinoma of the breast. *Annals of Surgical Oncology* **4**, 545–550.
 30. Skowron, G., Cole, B.F., Zheng, D. and Yen-Lieberman, B. (1997). HIV-1 gp120-directed antibody dependent cellular cytotoxicity (ADCC) as a mechanism for CD4 depletion in HIV-1 disease. *AIDS* **11**, 1807–1814.
 31. Schwartz, C.E., Coulthard-Morris, L., Cole, B.F. and Vollmer, T. (1997). The quality-of-life effects of interferon beta-1b in multiple sclerosis: an extended Q-TWiST analysis. *Archives of Neurology* **54**, 1475–1480.
 32. Wanebo, H.J., Chougule, P., Akerley, W.L., Koness, J., McRae, R., Nigri, P., Leone, L., Ready, N., Safran, H., Webber, B., and Cole, B. (1997). Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. *American Journal of Surgery* **174**, 518–522.
 33. Chougule, P., Wanebo, H., Akerley, W., McRae, R., Nigri, P., Leone, L., Safran, H., Ready, N., Koness, R.J., Radie-Keane, K., and Cole, B. (1997). Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study – preliminary results. *Seminars in Oncology* **24** (Supplement 19), 57–61.
 34. Chang, H.R., Cole, B. and Bland, K.I. (1997). Nonpalpable breast cancer in women aged 40-49 years: a surgeon's view of benefits from screening mammography. *Journal of the National Cancer Institute Monographs* **22**, 145–149.
 35. Glantz, M.J., Cole, B.F., Glantz, L.K., Mills, P., Cobb, J.L., Lekos, A., Walters, B.C. and Recht, L.D. (1998). Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. *Cancer* **82**, 733–739.
 36. Friedberg, M.H., Glantz, M.J., Klempner, M.S., Cole, B.F., and Perides, G. (1998). Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of

- malignant astrocytomas, brain metastases, and carcinomatous meningitis. *Cancer* **82**, 923–930.
37. Wheeler, C.A., Cole, B.F., Frishman, G.N., Seifer, D.B., Lovegreen, S.B., Hackett, R.J. (1998). Predicting probabilities of pregnancy and multiple gestation from in vitro fertilization—a new model. *Obstetrics & Gynecology* **91**, 696-700.
 38. Glantz, M.J., Cole, B.F., Recht, L., Akerley, W., Mills, P., Saris, S., Hochberg, F., Calabresi, P. and Egorin, M.J. (1998). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? *Journal of Clinical Oncology* **16**:1561–1567.
 39. Titus-Ernstoff, L., Egan, K.M., Newcomb, P.A., Baron, J.A., Stampfer, M., Greenberg, E.R., Cole, B.F., Ding, J., Willett, W., and Trichopoulos, D. (1998). Exposure to breast milk in infancy and adult breast cancer risk. *Journal of the National Cancer Institute* **90**, 921–924.
 40. Recht, L.D., Glantz, M.J., Meitner, P., Glantz, L., Akerley, W., Wahlberg, L., Saris, S. and Cole, B.F. (1998). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). *Journal of Neuro-Oncology* **36**, 201–208.
 41. Glasziou, P.P., Cole, B.F., Gelber, R.D., Hilden, J., and Simes, R.J. (1998). Quality-adjusted survival analysis with repeated quality-of-life measures. *Statistics in Medicine* **17**, 1215–1229.
 42. Cole, B.F., Solal-Céligny, P., Gelber, R.D., Lepage, E., Gisselbrecht, C., Reyes, F., Sebban, C., Sugano, D., Tendler, C. and Goldhirsch, A. (1998). Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decisionmaking. *Journal of Clinical Oncology* **16**, 2339–2344.
 43. Choy, H., Safran, H., Akerley, W., Graziano, S.L., Bogart, J.A. and Cole, B.F. (1998). Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. *Clinical Cancer Research* **4**, 1931–1936.
 44. Zee, B., Cole, B.F., Li, T., Browman, G., James, K., Johnston, D., Sugano, D., and Pater, J. (1998). Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. *Journal of Clinical Oncology* **16**, 2834–2839.
 45. Choy, H., Akerley, W., Safran, H., Graziano, S., Chung, C., Williams, T., Cole, B. and Kennedy, T. (1998). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. *Journal of Clinical Oncology* **16**, 3316–3322.
 46. Wehbe, T., Glantz, M., Choy, H., Glantz, L., Cortez, S., Akerley, W., Mills, P. and Cole, B. (1998). Histologic evidence of a radiosensitizing effect of taxol in patients with astrocytomas. *Journal of Neuro-Oncology* **39**, 245–251.
 47. Wanebo, H., Coburn, M., Teates, D., and Cole, B. (1998). Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. *Annals of Surgery* **6**, 912–921.
 48. Konstadoulakis, M.M., Vezeridis, M., Hatziyianni, E., Karakousis, C.P., Cole, B., Bland, K.I., and Wanebo, H.J. (1998). Molecular oncogene markers and their significance in cutaneous malignant melanoma. *Annals of Surgical Oncology* **5**, 253–260.
 49. Rosendahl, I., Kiebert, G.M., Curran, D., Cole, B.F., Weeks, J.C., Denis, L.J. and Hall, R.R. (1999). A quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. *The Prostate* **38**, 100–109.

50. Shraye, D.P., Cole, B., Hearing, V.J., Wolf, S.F., and Wanebo, H.J. (1999). Immunotherapy of mice with an irradiated melanoma vaccine coupled with interleukin-12. *Clinical & Experimental Metastasis* **17**, 63–70.
51. Parsons, S.K., Gelber, S., Cole, B.F., Ravindranath, Y., Ogden, A., Yeager, A.M., Chung, M., Shuster, J., Weinstein, H.J. and Gelber, R.D. (1999). Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: a Q-TWiST analysis of the pediatric oncology group study 8821. *Journal of Clinical Oncology* **17**, 2144–2152.
52. Bonetti, M., Cole, B.F. and Gelber, R.D. (1999). A method-of-moments estimation procedure for categorical quality-of-life data with nonignorable missingness. *Journal of the American Statistical Association* **94**, 1025–1034.
53. Schwaab, T., Schned, A.R., Heaney, J.A., Cole, B.F., Atzpodien, J., Wittke, F. and Ernstoff, M.S. (1999). In vivo description of dendritic cells in human renal cell carcinoma. *Journal of Urology* **162**, 567–573.
54. Glantz, M.J., Chamberlain, M.C., Chang, S.M., Prados, M.D. and Cole, B.F. (1999). The role of paclitaxel in the treatment of primary and metastatic brain tumors. *Seminars in Radiation Oncology* **9** (Supplement 1), 27–33.
55. Bensen, S.P., Cole, B.F., Mott, L.A., Baron, J.A., Sandler, R.S. and Haile, R. for the Polyps Prevention Study Group (1999). Colorectal hyperplastic polyps and risk of recurrence of adenomas and hyperplastic polyps. *The Lancet* **354**, 1873–1874.
56. Glantz, M.J., Jaekle, K.A., Chamberlain, M.C., Phuphanich, S., Recht, L., Swinnen, L.J., Maria, B., LaFollette, S., Schumann, G.B., Cole, B.F., Howell S.B. (1999). A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. *Clinical Cancer Research* **5**, 3394–3402.
57. Murray, S. and Cole, B. (2000). Variance and sample size calculations in quality of life adjusted survival analysis (Q-TWiST). *Biometrics* **56**, 173–182.
58. Mounier, N., Haioun, C., Cole, B.F., Gisselbrecht, C., Sebban, C., Morel, P., Marit, G., Bouabdallah, R., Ravoet, C., Salles, G., Reyes, F. and Lepage, E. for the GELA (Groupe d'Etude des Lymphomes de l'Adulte) (2000). Quality of life adjusted survival (Q-TWiST) analysis of high dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for aggressive lymphoma patients in first complete remission: the GELA LNH87-2 Study. *Blood* **95**, 3687–3692.
59. Cobb, J.L., Glantz, M.J., Nicholas, P.K., Martin, E.W., Paul-Simon, A., Cole, B.F. and Corless, I.B. (2000). Delirium in cancer patients at the end of life: a retrospective inpatient hospice study. *Cancer Practice* **8**, 172–177.
60. Glantz, M.J., Cole, B.F., Forsyth, P.A., Recht, L.D., Wen, P.Y., Chamberlain, M.C., Grossman, S.A. and Cairncross, J.G. (2000). Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* **54**, 1886–1893.
61. Schwaab, T., Heaney, J.A., Schned, A.R., Harris, R.D., Cole, B.F., Noelle, R.J., Phillips, D.M., Stempkowski, L. and Ernstoff, M.S. (2000). A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. *Journal of Urology* **163**, 1322–1327.

62. Font, A., Rigas, J.R., Eastman, A., Memoli, V.A., Cole, B.F., Hammond, S. and Rosell, R. (2000). Expression of apoptosis-related proteins and response to chemoradiotherapy and prognosis in esophageal cancer. *Revista de Oncología* **2**, 146–153.
63. Lewis, L.D., Cole, B.F., Wallace, P.K., Fisher, J.L., Waugh, M., Guyre, P.M., Fanger, M.W., Curnow, R.T., Kaufman, P.A. and Ernstoff, M.S. (2001). Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase I study in patients with advanced cancer which overexpresses HER-e/neu. *Journal of Immunological Methods* **248**, 149–165.
64. Schwaab, T., Lewis, L.D., Cole, B.F., Deo, Y., Fanger, M.W., Wallace, P., Guyre, P.M., Kaufman, P.A., Heaney, J.A., Schned, A.R., Harris, R.D. and Ernstoff, M.S. (2001). Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. *Journal of Immunotherapy* **24**, 79–87.
65. Cole, B.F., Gelber, R.D., Gelber, S., Coates, A.S. and Goldhirsch, A. (2001). Polychemotherapy for early breast cancer: an overview of the randomised trials with quality-adjusted survival analysis. *The Lancet* **358**, 277–286.
66. Ahles, T.A., Saykin, A., Furstenberg, C.T., Cole, B., Mott, L.A., Skalla, K., Whedon, M.B., Bivens, S., Mitchell, T., Greenberg, E.R., Silberfarb, P.M. (2002). Neuropsychological impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. *Journal of Clinical Oncology* **20**, 485–493.
67. Kilbridge, K.L., Cole, B.F., Kirkwood, J.M., Haluska, F.G., Atkins, M.A., Ruckdeschel, J.C., Sock, D.E., Nease, R.F. and Weeks, J.C. (2002). Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2B for high-risk melanoma patients using intergroup clinical trial data. *Journal of Clinical Oncology* **20**, 1311–1318.
68. Harper, D.M., Noll, W.W., Belloni, D.R. and Cole, B.F. (2002). Randomized clinical trial of PCR determined HPV detection methods: self-sampling vs. clinician directed. Biological concordance and women's preferences. *American Journal of Obstetrics and Gynecology* **186**, 365–373.
69. Lewis, L.D., Beelen, A.P., Cole, B.F., Wallace, P.K., Fisher, J.L., Waugh, M.G., Kaufman, P.A. and Ernstoff, M.S. (2002) The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer. *Cancer Chemotherapy and Pharmacology* **49**, 375–384.
70. Harper, D.M., Raymond, M., Noll, W.W., Belloni, D.R., Duncan, L.T. and Cole, B.F. (2002). Tampon samplings with longer cervico-vaginal cell exposures are equivalent to two consecutive swabs for the detection of high-risk human papillomavirus. *Sexually Transmitted Diseases* **29**, 628–636.
71. Shraye, D.P., Bogaars, H., Cole, B., Wolf, S.F. and Wanebo, H.J. (2002). Capacity of murine IL-12 to inhibit the development of primary melanoma tumors and to prevent lung metastases in the melanoma-challenged mice. *Journal of Experimental Therapeutics & Oncology* **2**, 93–99.
72. Baron, J.A., Cole, B.F., Sandler, R.S., Haile, R.W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R.W., Rothstein, R., Burke, C.A., Snover, D.C., Church, T.R., Allen, J.I., Beach, M., Beck, G.J., Bond, J.H., Byers, T., Greenberg, E.R., Mandel, J.S., Marcon, N., Mott, L.A., Pearson, L., Saibil, F. and van Stolk, R.U. (2003). A randomized trial of aspirin to prevent colorectal adenomas. *New England Journal of Medicine* **348**, 891–899.

73. Troisi, R., Potischman, N., Roberts, J.M., Harger, G., Markovic, N., Cole, B., Lykins, D., Siiteri, P. and Hoover, B.N. (2003). Correlation of serum hormone concentrations in maternal and umbilical cord samples. *Cancer Epidemiology, Biomarkers & Prevention* **12**, 452–456.
74. Baron, J.A., Cole, B.F., Mott, L., Haile, R., Grau, M., Church, T.R., Beck, G.J. and Greenberg, E.R. (2003). Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial. *Journal of the National Cancer Institute* **95**, 717–722.
75. Cole, B.F., Glantz, M.J., Jaeckle, K.A., Chamberlain, M.C. and Mackowiak, J.I. (2003). Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. *Cancer* **97**, 3053–3060.
76. Wallace, K., Byers, T., Morris, J.S., Cole, B.F., Greenberg, E.R., Baron, J.A., Gudino, A., Spate, V. and Karagas, M.R. (2003). Prediagnostic serum selenium concentration and the risk of recurrent colorectal adenoma: a nested case-control study. *Cancer Epidemiology, Biomarkers & Prevention* **12** 464–467.
77. Ahles, T.A., Saykin, A.J., Noll, W.W., Furstenberg, C.T., Guerin, S., Cole, B. and Mott, L.A. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. *Psycho-Oncology* **12**, 612–619.
78. Vuola, J.M., Ristola, M.A., Cole, B., Järviluoma, A., Tvaroha, S., Rönkkö, T., Rautio, O., Arbeit, R.D. and von Reyn, C.F. (2003). Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. *AIDS* **17**, 2351–2355.
79. Harper, D.M., Longacre, M.R., Noll, W.W., Belloni, D.R. and Cole, B.F. (2003). Factors affecting the detection rate of human papillomavirus. *Annals of Family Medicine* **1**, 221–227.
80. Cole, B.F., Gelber, R.D., Gelber, S. and Mukhopadhyay, P. (2004). A quality-adjusted survival model (Q-TWiST) for advanced stage cancer. *Journal of Biopharmaceutical Statistics* **14**, 111–124.
81. Schwaab, T., Tretter, C.P.G., Gibson, J.J., Cole, B.F., Schned, A.R., Harris, R., Wallen, E.M., Fisher, J.L., Waugh, M.G., Truman, D., Stempkowski, L.M., Crosby, N.A., Heaney, J.A. and Ernstoff, M.S. (2004). Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. *Journal of Urology* **171**, 1036–1042.
82. Wallace, K., Baron, J.A., Cole, B.F., Sandler, R.S., Karagas, M.R., Beach, M.A., Haile, R.W., Burke, C.A., Pearson, L.H., Mandel, J.S., Rothstein, R. and Snover, D.C. (2004). Effect of calcium supplementation on the risk of large bowel polyps. *Journal of the National Cancer Institute* **96**, 921–925.
83. Buckley, J.C., Alvarenga, D., Cole, B. and Rigas, J.R. (2004). Chlorpheniramine for motion sickness. *Journal of Vestibular Research* **14**, 53–61.
84. Ferguson, R.J., Seville, J., Cole, B., Hanscom, B., Wasson, J.H., Johnson, D.J. and Ahles, T. (2004). Psychometric update of the Functional Interference Estimate: a brief measure of pain functional interference. *Journal of Pain and Symptom Management* **28**, 389–395.
85. Mtei, L., Matee, M., Herfort, O., Bakari, M., Horsburgh, C.R., Waddell, R., Cole, B.F., Vuola, J.M., Tvaroha, S., Kreiswirth, B., Pallangyo, K. and von Reyn, C.F. (2005). High

- rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. *Clinical Infectious Diseases* **40**, 1500–1507.
86. Titus-Ernstoff, L., Perry, A.E., Spencer, S.K., Gibson, J.J., Cole, B.F. and Ernstoff, M.S. (2005). Pigmentary characteristics and moles in relation to melanoma risk. *International Journal of Cancer* **116**, 144–149.
 87. Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L.A., Titus-Ernstoff, L., Skalla, K., Bakitas, M. and Silberfarb, P.M. (2005). Quality of life of long-term survivors of breast cancer and lymphoma treated with standard dose chemotherapy or local therapy. *Journal of Clinical Oncology* **23**, 4399–4405.
 88. Cole, B.F., Bonetti, M., Zaslavsky, A.M. and Gelber, R.D. (2005). A multi-state Markov chain model for longitudinal, categorical quality-of-life data subject to nonignorable missingness. *Statistics in Medicine* **24**, 2317–2334.
 89. Irish, W., Sherrill, B., Cole, B., Gard, C., Glendenning, G.A. and Mouridsen, H. (2005). Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. *Annals of Oncology* **16**, 1458–1462.
 90. Robertson, D.J., Greenberg, E.R., Beach, M. Sandler, R.S., Ahnen, D., Haile, R.W., Burke, C.A., Snover, D.C., Bresalier, R.S., McKeown-Eyssen, G. Mandel, J.S., Bond, J.H., van Stolk, R.U., Summers, R.W., Rothstein, R. Church, T.R., Cole, B., Byers, T., Mott, L. Baron, J.A. (2005). Colorectal cancer in patients under close colonoscopic surveillance. *Gastroenterology* **129**, 34–41.
 91. Crocenzi, T.S., Tretter, C.P.G., Schwaab, T., Schned, A.R., Heaney, J.A., Cole, B.F., Fisher, J.L. and Ernstoff, M.S. (2005). Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients. *Clinical Immunology* **117**, 6–11.
 92. Pipas, J.M., Barth, R.J. Jr., Zaki, B., Tsapakos, M.J., Suriawinata, A.A., Bettmann M.A., Cates, J.M., Ripple, G.H., Sutton, J.E., Gordon, S.R., McDonnell, C.E., Perez, R.P., Redfield, N., Meyer, L.P., Marshall, J.F., Cole, B.F. and Colacchio, T.A. (2005). Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. *Annals of Surgical Oncology* **12**, 995–1004.
 93. Grau, M.V., Baron, J.A., Barry, E.L., Sandler, R.S., Haile, R.W., Mandel, J.S. and Cole, B.F. (2005). Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. *Cancer Epidemiology, Biomarkers & Prevention* **14**, 2353–2358.
 94. Wallace, K., Baron, J.A., Karagas, M.R., Cole, B.F., Byers, T., Beach, M.A., Pearson, L.H., Burke, C.A., Silverman, W.B. and Sandler, R.S. (2005). The association of physical activity and body mass index with the risk of large bowel polyps. *Cancer Epidemiology, Biomarkers & Prevention* **14**, 2082–2086.
 95. Titus-Ernstoff, L., Perry, A.E., Spencer, S.K., Gibson, J., Cole, B., and Ernstoff, M.S. (2006). Multiple primary melanoma: Two-year results from a population-based study. *Archives of Dermatology* **142**, 433–438.
 96. Revicki, D., Feeny, D., Hunt, T.L. and Cole, B.F. (2006). Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. *Quality of Life Research* **15**, 411–423.
 97. Schwaab, T., Tretter, C.P.G., Gibson, J.J., Cole, B.F., Schned, A.R., Harris, R., Fisher, J.L., Crosby, N., Stempkowski, L.M., Heaney, J.M. and Ernstoff, M.S. (2006). Tumor-related Immunity in Prostate Cancer Patients Treated with Human Recombinant Granulocyte Monocyte Colony Stimulating Factor (GM-CSF). *The Prostate* **66**, 667–674.

98. Wu, J.Y., Ernstoff, M.S., Hill, J.M., Cole, B. and Meehan, K.R. (2006). Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. *Cytotherapy* **8**, 141–148.
99. Omlin, A., Amichetti, M., Azria, D., Cole, B.F., Fournier, P., Poortmans, P., Naehrig, D., Miller, R.C., Krengli, M., Miguelez, C.G., Morgan, D., Goldberg, H., Scandolaro, L., Gastelblum, P., Ozsahin, M., Dohr, D., Christie, D., Oppitz, U., Abacioglu, U. and Gruber, G. (2006). Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. *The Lancet Oncology* **7**, 652–656.
100. Wells, W.A., Schwartz, G.N., Morganelli, P.M., Cole, B.F., Gibson, J.J. and Kinlaw, W.B. (2006). Expression of “Spot 14” (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. *Breast Cancer Research and Treatment* **98**, 231–240.
101. Ahles, T.A., Wasson, J.H., Seville, J.L., Johnson, D.J., Cole, B.F., Hanscom, B., Stukel, T. and McKinstry, E. (2006). A controlled trial of methods for managing pain in primary care patients with or without co-occurring psychosocial problems. *Annals of Family Medicine* **4**, 341–350.
102. Troisi, R., Vatten, L., Hoover, R.N., Roberts, J.M., Cole, B.F. and Potischman, N. (2006). Maternal androgen and estrogen concentrations are not associated with blood pressure changes in uncomplicated pregnancies. *Cancer Epidemiology, Biomarkers & Prevention* **15**, 2013–2015.
103. Kim, S., Baron, J.A., Mott, L.A., Burke, C.A., Church, T.R., McKeown-Eyssen, G.E., Cole, B.F., Haile, R.W. and Sandler, R.S. (2006). Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). *Cancer Causes and Control* **17**, 1299–304.
104. Troisi, R., Masters, M.N., Joshipura, K., Douglass, C., Cole, B.F. and Hoover, R.N. (2006). Perinatal factors, growth and development, and osteosarcoma risk. *British Journal of Cancer* **95**, 1603–1607.
105. Matee, M., Lahey, T., Vuola, J.M., Mtei, L., Cole, B.F., Bakari, M., Arbeit, R.D., Horsburgh, C.R., Pallangyo, K. and von Reyn, C.F. (2007). Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. *Journal of Infectious Diseases* **195**, 118–123.
106. Grau, M.V., Baron, J.A., Sandler, R.S., Wallace, K., Haile, R.W., Church, T.R., Beck, G.J., Summers, R.W., Barry, E.L., Cole, B.F., Snover, D.C., Rothstein, R. and Mandel, J.S. (2007). Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. *Journal of the National Cancer Institute* **99**, 129–136.
107. Titus-Ernstoff, L., Ding, J., Perry, A., Spencer, S., Cole, B. and Ernstoff, M. (2007). Factors associated with atypical moles in New Hampshire, USA. *Acta Dermato-Venereologica* **87**, 43–48.
108. Ernstoff, M.S., Crocenzi, T.S., Seigne, J.D., Crosby, N.A., Cole, B.F., Fisher, J.L., Uhlenhake, J.C., Mellinger, D., Foster, C., Farnham, C.J., Mackay, K., Szczepiorkowski, Z.M., Webber, S.M., Schned, A.R., Harris, R.D., Barth, R.J. Jr., Heaney, J.A. and Noelle, R.J. (2007). Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. *Cancer Clinical Research* **13**, 733s–740s.
109. Karlsson, P., Cole, B.F., Price, K.N., Coates, A.S., Castiglione-Gertsch, M., Gusterson, B.A., Murray, E., Lindtner, J., Collins, J.P., Holmberg, S.B., Fey, M.F., Thürlimann, B., Crivellari, D., Forbes, J.F., Gelber, R.D., Goldhirsch, A. and Wallgren A. for the

- International Breast Cancer Study Group (2007). Factors predicting locoregional recurrence among breast cancer patients: role of the number of uninvolved lymph nodes. *Journal of Clinical Oncology* **25**, 2019–2026.
110. Olson, A.L., Gaffney, C., Starr, P., Gibson, J.J., Cole, B.F. and Dietrich, A.J. (2007). SunSafe in the Middle School Years: a community-wide intervention to change early-adolescent sun protection. *Pediatrics* **119**, e247–e256.
111. Ferguson, R.J., Ahles, T.A., Saykin, A.J., McDonald, B.C., Furstenberg, C.T., Cole, B.F. and Mott, L.A. (2007). Cognitive-behavioral management of chemotherapy-related cognitive change. *Psycho-Oncology* **16**, 772–777.
112. Cole, B.F., Baron, J.A., Sandler, R.S., Haile, R.W., Ahnen, D.J., Bresalier, R.S., McKeown-Eyssen, G., Summers, R.W., Rothstein, R.I., Burke, C.A., Snover, D.C., Church, T.R., Allen, J.I., Robertson, D.J., Beck, G.J., Bond, J.H., Byers, T., Mandel, J.S., Mott, L.A., Pearson, L.H., Barry, E.L., Rees, J.R., Marcon, N., Saibil, F., Ueland, P.M. and Greenberg, E.R. For the Polyp Prevention Study Group (2007). A randomized trial of folic acid for the prevention of colorectal adenomas. *Journal of the American Medical Association* **297**, 2351–2359.
113. Gianni, L., Cole, B.F., Panzini, I., Snyder, R., Holmberg, S.B., Byrne, M., Crivellari, D., Colleoni, M., Aebi, S., Simoncini, E., Pagani, O., Castiglione-Gertsch, M., Price, K.N., Goldhirsch, A., Coates, A.S. and Ravaioli, A. (2008). Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. *Supportive Care in Cancer* **16**, 67–74.
114. Gruber, G., Cole, B.F., Castiglione-Gertsch, M., Holmberg, S.B., Lindtner, J., Golouh, R., Collins, J., Crivellari, D., Thurlimann, B., Simoncini, E., Fey, M.F., Gelber, R.D., Coates, A.S., Price, K.N., Goldhirsch, A., Viale, G. and Gusterson, B.A. (2008). International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. *Annals of Oncology* **19**, 1393–401.
115. Ahles, T.A., Saykin, A.J., McDonald, B.C., Furstenberg, C.T., Cole, B.F., Hanscom, B.S., Mulrooney, T.J., Schwartz, G.N. and Kaufman, P.A. (2008). Cognitive function in breast cancer patients prior to adjuvant treatment. *Breast Cancer Research and Treatment* **110**, 143–52.
116. Titus-Ernstoff, L., Troisi, R., Hatch, E.E., Hyer, M., Wise, L.A., Palmer, J.R., Kaufman, R., Adam, E., Noller, K., Herbst, A.L., Strohsnitter, W., Cole, B.F., Hartge, P. and Hoover, R.N. (2008). Offspring of women exposed in utero to diethylstilbestrol (DES): a preliminary report of benign and malignant pathology in the third generation. *Epidemiology* **19**, 251–257.
117. Bakari, M., Arbeit, R.D., Mtei, L., Lyimo, J., Waddell, R.D., Matee, M., Cole, B.F., Tvaroha, S., Horsburgh, C.R., Soini, H., Pallangyo K. and von Reyn, C.F (2008). Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. *BMC Infectious Diseases* **8**, 32.
118. Levine, A.J., Wallace, K., Tsang, S., Haile, R.W., Saibil, F., Ahnen, D., Cole, B.F., Berry, E.L., Munroe, D.J., Ali, I.U., Ueland, P. and Baron, J.A. (2008). MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial. *Cancer Epidemiology Biomarkers & Prevention* **17**, 2409–2415.

119. Fadul, C.E., Kingman, L.S., Meyer, L.P., Cole, B.F., Eskey, C.J., Rhodes, C.H., Roberts, D.W., Newton, H.B. and Pipas, J.M. (2008). A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. *Journal of Neuro-Oncology* **90**, 229–235.
120. Cole, B.F., Logan, R.F., Halabi, S., Benamouzig, R., Sandler, R.S., Grainge, M.J., Chaussade, S. and Baron, J.A. (2009). Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. *Journal of the National Cancer Institute* **101**, 256–266.
121. Kanski, A.A., Andre, A., Winter, K., Cole, B.F., Ang, K.K. and Fu, K.K. (2009). Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. *Head and Neck—Journal for the Sciences and Specialties of the Head and Neck* **31**, 207–212.
122. Robertson, D.J., Sandler, R.S., Ahnen, D., Greenberg, E.R., Mott, L.A., Cole, B.F. and Baron, J.A. (2009). Gastrin, Helicobacter pylori and colorectal adenomas. *Clinical Gastroenterology and Hepatology* **7**, 163–167.
123. Bonetti, M., Zahrieh, D., Cole, B.F. and Gelber, R.D. (2009). A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data. *Statistics in Medicine* **28**, 1255–1268.
124. Mongan, J.P., Fadul, C.E., Cole, B.F., Zaki, B.I., Suriawinata, A.A., Ripple, G.H., Tosteson, T.D. and Pipas, J.M. (2009). Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. *Clinical Colorectal Cancer* **8**, 100–105.
125. Schwaab, T., Schwarzer, A., Wolf, B., Crocenzi, T.S., Seigne, J.D., Crosby, N.A., Cole, B.F., Fisher, J.L., Uhlenhake, J.C., Mellinger, D., Foster, C., Szczepiorkowski, Z.M., Webber, S.M., Schned, A.R., Harris, R.D., Barth, R.J., Heaney, J.A., Noelle, R.J. and Ernstoff, M.S. (2009). Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN- α 2a therapy in metastatic renal cell carcinoma patients. *Clinical Cancer Research* **15**, 4986–4992.
126. Barth, R.J., Wells, W.A., Mitchell, S.E. and Cole, B.F. (2009). A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. *Annals of Surgical Oncology* **16**, 2288–2294.

OTHER PUBLICATIONS (NON-PEER-REVIEWED):

1. Cole, B.F. (1992). A parametric method for performing cost-benefit analysis in the presence of competing risks and multiple events. Ph.D. dissertation, Boston University, Department of Mathematics, Boston, MA.
2. Gelber, R.D., Cole, B.F. and Goldhirsch, A. (1993). How to compare quality of life of breast cancer patients in clinical trials. In: Senn, H.J., Gelber, R.D., Goldhirsch, A. and Thürlimann, B., eds. *Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research*, Vol. 127, pp. 221–233, Berlin: Springer-Verlag.
3. Cole, B.F., Gelber, R.D., Anderson, K.M. and Goldhirsch, A. (1995). Cost-effectiveness analysis using quality-of-life-adjusted survival. In: *1994 Proceedings of the Biopharmaceutical Section, American Statistical Association*, Alexandria, VA.
4. Gelber, R.D., Cole, B.F., Gelber, S. and Goldhirsch, A. (1995). The Q-TWiST method. In: Spilker, B., ed. *Quality of Life and Pharmacoeconomics in Clinical Trials*, pp. 437–444, Philadelphia: Lippincott-Raven.

5. Cole, B.F. (1996). Evaluating the clinical and economic trade-offs of hepatic arterial infusion (editorial). *Journal of the National Cancer Institute* **88**, 223–224.
6. Cole, B.F., Gelber, R.D. and Kirkwood, J.M. (1998). Survival benefit in melanoma (letter). *Journal of Clinical Oncology* **16**, 388–389.
7. Gelber, S., Gelber, R.D., Cole, B.F. and Goldhirsch, A. (1998). Using the Q-TWiST method for treatment comparisons in clinical trials. In: Staquet, M.J., Hays, R.D. and Fayers, P.M., eds. *Quality of Life Assessment in Clinical Trials: Methods and Practice*. New York: Oxford University Press.
8. Cole, B.F., Gelber, R.D. and Gelber, S. (1998). Evaluation of quality of life in cancer clinical trials. In: Kirkwood, J.M., Lotze, M.T. and Yasko, J.M., eds. *Current Cancer Therapeutics, 3rd Edition*. Philadelphia: Current Medicine, Inc.
9. Cole, B.F., Gelber, R.D. and Goldhirsch, A. (1998). In reply (letter). *Journal of Clinical Oncology* **16**, 3718.
10. Gelber, R.D., Bonetti, M., Cole, B.F., Gelber, S. and Goldhirsch, A. (1998). Quality of life assessment in the adjuvant setting: is it relevant? In: Senn, H.J., Gelber, R.D., Goldhirsch, A. and Thürlimann, B., eds. *Adjuvant Therapy of Primary Breast Cancer VI*. pp. 373–389, Berlin: Springer-Verlag.
11. Brown, D.L., Cole, B.F. and Arrick, B.A. (1999). Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations (letter). *Journal of the National Cancer Institute* **91**, 90-91.
12. Cole, B.F. (2001). Design and analysis considerations for complementary outcomes. In: Crowley, J, ed. *Handbook of Statistics in Clinical Oncology*. pp. 229–248, New York: Marcel Dekker.
13. Cole, B.F., Gelber, R.D. and Gelber, S. (2001). Evaluation of quality of life in cancer clinical trials. In: Kirkwood, J.M., Lotze, M.T. and Yasko, J.M., eds. *Current Cancer Therapeutics, 4th Edition*. Philadelphia: Current Medicine, Inc.
14. Cole, B.F., Gelber, R.D., Gelber, S., Coates, A.S. and Goldhirsch, A. (2001). Author's reply (letter). *The Lancet* **358**, 2170.
15. Mesbah, M., Cole, B.F. and Lee, M.-L.T., eds. (2002). *Statistical Methods for Quality of Life Studies*. Dordrecht: Kluwer.
16. Cole, B.F. and Kilbridge, K.L. (2002). Quality-adjusted survival analysis in cancer clinical trials. In: Mesbah, M., Cole, B.F. and Lee, M.-L.T., eds. *Statistical Methods for Quality of Life Studies*. Dordrecht: Kluwer.
17. Cole, B.F., Gelber, S. and Gelber, R.D. (2005). Software tools for quality-adjusted survival analysis using Q-TWiST. In: Lenderking, W.R. and Revicki, D.A., eds. *Advancing Health Outcomes Research Methods in Clinical Applications*. McLean, VA: Degnon Associates.
18. Revicki, D., Feeny, D., Hunt, T.L. and Cole, B.F. (2006). Clinically important differences in Q-TWiST—One TWiST too many or TWiST and shout? (letter). *Quality of Life Research* **15**, 427–428.
19. Cole, B.F., Baron, J.A., Mott, L.A. (2007). Folic acid and prevention of colorectal adenomas—reply (letter). *Journal of the American Medical Association* **298**, 1397.
20. Mason, J.B., Cole, B.F., Baron, J.A., Kim, Y.I., Smith, A.D. (2008). Folic acid fortification and cancer risk (letter). *Lancet* **371**, 1335.
21. Bonetti, M., Cole, B.F. and Gelber, R.D. (2008) Another STEPP in the right direction (letter). *Journal of Clinical Oncology* **26**, 3813–3814.

GRANT SUPPORT (AWARDED WITHIN LAST FIVE YEARS)

Granting Agency: NIH/NCI

Project Title: Aspirin/Folate Prevention of Large Bowel Polyps

Role: Project Statistician

Principle Investigator: John Baron

Institution: Dartmouth Medical School

Description: This project is a large randomized clinical trial of aspirin and folate supplementation for the prevention of colorectal adenomas in individuals with a history of these lesions.

Granting Agency: NIH/NCI

Project Title: Vitamin D/Calcium Polyp Prevention Study

Role: Project Statistician

Principle Investigator: John Baron

Institution: Dartmouth Medical School

Description: This project is a large randomized clinical trial of vitamin D and calcium supplementation for the prevention of colorectal adenomas in individuals with a history of these lesions.

Granting Agency: NIH/NCI

Project Title: Cancer Center Support Grant

Role: Director, Biostatistics Shared Resource

Principle Investigator: Mark Israel

Institution: Dartmouth Medical School

Description: This grant provides core support for the Norris Cotton Cancer Center in Lebanon, NH, including the Biostatistics Shared Resource, which provides statistical expertise to cancer investigators.

Granting Agency: NIH/DAIDS

Project Title: Disseminated Tuberculosis in HIV Infection

Role: Project Statistician

Principle Investigator: C. Fordham von Reyn

Institution: Dartmouth Medical School

Description: This project, which takes place in Tanzania, is a large randomized clinical trial of a vaccine designed to prevent disseminated tuberculosis infection in patients with HIV infection.

Granting Agency: Frontier Science and Technology Research Foundation

Project Title: Statistical Support for the IBCSG

Principle Investigator: Bernard F. Cole

Institution: University of Vermont

Description: This project provides statistical support for the International Breast Cancer Study group, an international collaborative clinical trial group that conducts large randomized studies of novel breast cancer chemotherapy.